Patient acceptability of CITOBOT for cervical cancer screening: A mixed-method study.
Journal:
PloS one
Published Date:
Jun 24, 2025
Abstract
This study assessed the acceptability of CITOBOT, a device for early cervical cancer screening in a real-world pilot setting as part of a translational research project aimed at designing and clinically validating a portable, cost-effective device supported by artificial intelligence. The authors adopted the Theoretical Framework of Acceptability for its utility in evaluating patient acceptability within complex interventions' development, piloting, and feasibility phases. We employed a mixed-method study, with 20 consecutive participants recruited from a specialized cancer healthcare center in Cali, Colombia. Data collection included a sociodemographic, gynecological-obstetric, behavioral survey, a validated patient acceptability scale, alongside open-ended interview questions. No adverse effects were reported seven days post-testing. The findings were promising, with all participants expressing high overall acceptability. Retrospective acceptability, focusing on the evaluation after device pilot testing, revealed that participants felt comfortable with the device, found it coherent with the purpose of early cervical cancer detection, and did not perceive the test as an additional burden compared to conventional cytology screening. Regarding prospective acceptability, which assesses anticipated acceptability before full implementation, three results stand out: i) All participants stated that they would intend to attend their health service if called for testing with CITOBOT; ii) they perceived opportunity costs, such as timely delivery of results, expedited diagnosis and treatment, and improved accessibility for women with limited resources or geographical barriers to healthcare access; and iii) participants viewed CITOBOT as highly effective in preventing cervical cancer deaths, indicating a strong belief in its potential to impact public health outcomes positively. Addressing concerns related to discomfort, inconvenience, and timely delivery of results, CITOBOT shows promise in enhancing cervical cancer screening participation and adherence, especially among underserved populations.
